Hyperhidrosis Therapeutics Pipeline 2017 - Clinical Trials & Results, Development

1
Hyperhidrosis Therapeutics Pipeline to Witness
Numerous Collaborations in Future
2
Hyperhidrosis Therapeutics
Hyperhidrosis therapeutics pipeline in 2017
The study analyzed that the hyperhidrosis
therapeutics pipeline comprises approximately 12
drug candidates in different stages of
development. Access Report summary with Detailed
TOC on "Hyperhidrosis Therapeutics Pipeline
Analysis, 2017 - Clinical Trials Results,
Patents, Designations, Collaborations, and Other
Developments" at https//www.psmarketresearch.com
/market-analysis/hyperhidrosis-therapeutics-pipeli
ne-analysis
3
Hyperhidrosis Therapeutics
Insights on pipeline segments
Allergan Plc, TheraVida Inc., and GlaxoSmithKline
Plc have one drug candidate each in the Phase II
development for the treatment of hyperhidrosis.
Glycopyrronium tosylate is the only drug
candidate that has the Phase III stage of
development for the treatment of hyperhidrosis.
Majority of the pipeline drug candidates are
being developed using the topical route of
administration.
4
Hyperhidrosis Therapeutics
Various collaborations for hyperhidrosis drug
development
In March 2015, Kaken Pharmaceutical Co., Ltd. and
Brickell Biotech, Inc. entered in an agreement
concerning the exclusive licensing and joint
development of BBI-4000. Under the terms of
agreement Brickell Biotech, Inc. agreed to
conduct a Phase IIb clinical trial of BBI-4000 in
the U.S. for patients with primary focal
hyperhidrosis.. Some of the key players
developing drugs for the treatment of
hyperhidrosis include Dermira, Inc., Allergan
plc, TheraVida Inc. and others.
5
Hyperhidrosis Therapeutics
Download report sample at
https//www.psmarketresearch.com/market-analysis/h
yperhidrosis-therapeutics-pipeline-analysis/report
-sample
6
GET IN TOUCH
THANK YOU!
For information regarding permissions and other
queries Kindly write to
US/Canada Toll-Free 1-888-778-7886